Individualized Treatment of Patients With Chronic Tinnitus With Repetitive Transcranial Magnetic Stimulation (indiTMS)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Regensburg, Germany, 93053
- Department of Psychiatry and Psychotherapy, University of Regensburg
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion criteria:
- chronic tinnitus (> 6 months)
- at least moderate tinnitus distress
- no or consistent medication
- no or consistent Treatments
- residence in Germany and German speaking
Exclusion Criteria:
- objective tinnitus
- serious and not stable illness (e.g. acute psychosis, severe depression or substance dependence, epilepsy, brain tumor)
- meeting the contraindications for transcranial magnetic stimulation or magnetic resonance imaging (electric devices or metal implants in the body, e.g. cardiac pace maker, insulin pump)
- neurological disorders (e.g. cerebrovascular events, neurodegenerative disorder, epilepsy, brain malformation, severe head trauma)
- addictive disorder with consumption in the last two years
- regular intake of benzodiazepines
- participation in another study parallel to the trial
- pregnancy or breastfeeding period
- psychiatric confinement
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: individualized rTMS
Treatment with the best (highest reduction in tinnitus loudness, most reliable, superior to control condition, most tolerable) protocol as obtained in the test sessions (left vs. right temporoparietal junction, 1Hz, 10Hz, 20Hz, 0.1Hz as active control condition).
|
Stimulation of the temporoparietal junction with repetitive transcranial magnetic stimulation
|
|
Active Comparator: standard rTMS in responders
Treatment with standard protocol: left-sided 1Hz in the group of patients who showed temporary reductions in tinnitus loudness in test sessions.
|
Stimulation of the temporoparietal junction with repetitive transcranial magnetic stimulation
|
|
Active Comparator: standard rTMS in non-responders
Treatment with standard protocol: left-sided 1Hz in the group of patients who did not show temporary reductions in tinnitus loudness in test sessions.
|
Stimulation of the temporoparietal junction with repetitive transcranial magnetic stimulation
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
TFI
Time Frame: 2 weeks
|
Tinnitus Functional Index
|
2 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
TFI
Time Frame: 12 weeks
|
Tinnitus Functional Index
|
12 weeks
|
|
Mini-TQ
Time Frame: 12 weeks
|
Tinnitus Questionnaire short version
|
12 weeks
|
|
THI
Time Frame: 12 weeks
|
Tinnitus Handicap inventory
|
12 weeks
|
|
Tinnitus Severity
Time Frame: 12 weeks
|
Tinnitus numeric Rating scales [0(best) - 10(worst)]
|
12 weeks
|
|
MDI
Time Frame: 12 weeks
|
Major Depression Inventory
|
12 weeks
|
|
WHO-QOL BREF
Time Frame: 12 weeks
|
Quality of life [4(worst) - 20(best)]
|
12 weeks
|
|
CGI
Time Frame: 12 weeks
|
clinical global Impression Change [1(best) - 7(worst)]
|
12 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Berthold Langguth, University of Regensburg
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 17-820-101
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.